MetaCap

Replimune Group Insider Trades

NASDAQ: REPLHealthcareBiotechnologyUSD

13.42+0.38 (+2.91%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Last 12 months

Purchases
0 · $0
Sales
17 · $1.93M
Shares bought / sold
0 / 216.59K
Net activity
Net selling $1.9 million

Replimune Group insider activity

Over the last 12 months, Replimune Group insiders reported 31 transactions on SEC Form 4: 0 open-market purchases and 17 sales. Insiders bought $0 and sold $1.9 million worth of stock, for net insider selling of $1.9 million. The largest seller was Patel Sushil, with $811,159 in reported sales.

The most recent filing shows Astley-Sparke Philip (Director) reporting a transaction in 50,000 shares on Aug 20, 2026. Insider sales are common for compensation, tax and diversification reasons, while open-market purchases are rarer; tracking both helps put REPL's ownership changes in context.

Summary generated from market data by MetaCap's automated system. Methodology

REPL insider transactions

Replimune Group insider transactions
DateInsiderTypeSharesValueFiling
Aug 20, 2026Astley-Sparke PhilipDirectorGift50,000—Form 4
Aug 17, 2026Hill Emily LuisaChief Financial OfficerSale9,256$132.18KForm 4
Aug 10, 2026Schwendenman AndrewChief Accounting OfficerSale7,632$98.99KForm 4
Aug 10, 2026Xynos KonstantinosChief Medical OfficerSale11,447$148.47KForm 4
Aug 10, 2026Patel SushilChief Executive OfficerSale39,341$510.25KForm 4
Aug 10, 2026Hill Emily LuisaChief Financial OfficerSale11,448$148.48KForm 4
Jun 1, 2026Sarchi ChristopherChief Commercial OfficerSale12,000$110.88KForm 4
May 18, 2026Hill Emily LuisaChief Financial OfficerSale7,812$39.68KForm 4
May 18, 2026Patel SushilChief Executive OfficerSale37,324$189.61KForm 4
May 18, 2026Astley-Sparke PhilipDirectorSale17,657$89.70KForm 4
May 18, 2026Sarchi ChristopherChief Commercial OfficerSale8,626$43.82KForm 4
May 18, 2026Schwendenman AndrewChief Accounting OfficerSale7,894$40.10KForm 4
May 18, 2026Xynos KonstantinosChief Medical OfficerSale14,023$71.24KForm 4
Apr 2, 2026Sarchi ChristopherChief Commercial OfficerSale6,500$52.06KForm 4
Apr 1, 2026Hill Emily LuisaChief Financial OfficerAward50,000—Form 4
Apr 1, 2026Sarchi ChristopherChief Commercial OfficerAward50,000—Form 4
Apr 1, 2026Patel SushilChief Executive OfficerAward251,240—Form 4
Apr 1, 2026Schwendenman AndrewChief Accounting OfficerAward36,667—Form 4
Apr 1, 2026Xynos KonstantinosChief Medical OfficerAward50,000—Form 4
Apr 1, 2026Astley-Sparke PhilipDirectorAward50,000—Form 4
Feb 18, 2026Astley-Sparke PhilipDirectorGift25,000—Form 4
Dec 19, 2025Sarchi ChristopherChief Commercial OfficerAward35,000—Form 4
Dec 19, 2025Patel SushilChief Executive OfficerAward200,000—Form 4
Dec 19, 2025Schwendenman AndrewChief Accounting OfficerAward10,000—Form 4
Dec 19, 2025Hill Emily LuisaChief Financial OfficerAward60,000—Form 4
Dec 19, 2025Xynos KonstantinosChief Medical OfficerAward60,000—Form 4
Dec 9, 2025Dhingra KapilDirectorSale3,169$32.96KForm 4
Dec 9, 2025Dhingra KapilDirectorOption exercise3,169$5.55KForm 4
Dec 2, 2025Patel SushilChief Executive OfficerSale10,000$111.30KForm 4
Nov 17, 2025Xynos KonstantinosChief Medical OfficerSale7,248$65.96KForm 4
Nov 17, 2025Sarchi ChristopherChief Commercial OfficerSale5,208$47.39KForm 4
Aug 15, 2025Hill Emily LuisaChief Financial OfficerSale9,154$49.16KForm 4

Transaction codes follow SEC Form 4: P = open-market purchase, S = open-market sale, A = grant or award, M = option exercise, F = shares withheld for taxes. About Form 4

Related